Edith Mary Dullaghan

Title: The Innovations of Edith Mary Dullaghan

Introduction

Edith Mary Dullaghan is a notable inventor based in Vancouver, Canada. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific diseases. Her work has the potential to impact various medical conditions, showcasing her dedication to innovation in healthcare.

Latest Patents

Dullaghan holds a patent for "MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof." This patent describes a series of compounds designed to inhibit MAO, which can be utilized in the treatment of barrier diseases, obesity, solid epithelial cell tumor metastasis, diabetes, autoimmune and inflammatory diseases, as well as cardiometabolic disorders. She has successfully developed a compound structure that could lead to significant advancements in therapeutic applications.

Career Highlights

Throughout her career, Dullaghan has worked with esteemed institutions such as the University of British Columbia and the Centre for Drug Research and Development. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Dullaghan has collaborated with notable colleagues, including Edward Ewald Putnins and David Grierson. These partnerships have enriched her research and expanded the scope of her innovations.

Conclusion

Edith Mary Dullaghan's contributions to pharmaceutical innovation are commendable. Her patent for MAO-B selective inhibitors exemplifies her commitment to addressing critical health issues. Through her work, she continues to pave the way for advancements in medical treatments.